PHIA Koninklijke Philips N.V.

Health technology leader Philips recognized as Clarivate Top 100 Global Innovator

Health technology leader Philips recognized as Clarivate Top 100 Global Innovator

March 6, 2024

Company’s innovative products and solutions improved the lives of 1.9 billion people in 2023

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, has been included in the . Philips’ global R&D programs and collaborations aim to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Together with healthcare providers and other ecosystem partners, Philips co-creates innovations that increase access to healthcare globally and create sustainable and resilient healthcare models.

For example, illustrating the global reach of its efforts to accelerate more productive and sustainable MR imaging operations, Philips has with its virtually helium-free BlueSeal magnet, which requires only 0.5% of the helium of a conventional Philips MR system. Additionally, Philips recently launched its and advanced informatics to enhance the minimally invasive diagnosis and treatment of neurovascular patients and reduce the time clinicians require per patient.

Roy Jakobs, CEO of Royal Philips said: “At Philips, we’ve been innovating to improve lives for over 130 years. People’s needs are at the very heart of how we innovate and design for sustainable impact with a ‘safety and quality first’ mindset. Innovation is our core strength and will continue to be our core differentiator. Recent industry trends have accelerated the adoption of technology within healthcare. We are embracing these trends and shifting our innovation to a more patient- and people-centric model closer to our customers.”

Further examples of innovations that help clinicians increase productivity and save time include Philips’ recently introduced next-generation with AI and expanded tele-ultrasound capability, and Philips’ recently launched , a cloud-based Picture Archiving and Communication System with high-speed remote access for diagnostic reading and AI-enabled workflow orchestration.

The Top 100 Global Innovators uses a comparative analysis of global invention data to assess the strength of every patented idea, using measures tied directly to their innovative power. Philips has now been included in this reputable list for eleven consecutive years and is the highest ranked company in the ‘Medical and biotechnology’ industry in the 2024 report. The full report can be found .

For further information, please contact:

Ben Zwirs

Philips External Relations

Tel.:

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring, and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,700 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachments



EN
06/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips publishes its Annual Report 2025

Philips publishes its Annual Report 2025 February 19, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025. Philips’ Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course. Philips filed the Annual Report 2025 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to f...

 PRESS RELEASE

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI ...

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI coil for its 3.0T MR systems, helping to enhance imaging precision, efficiency and comfort February 12, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the availability of the InkSpace Imaging Snuggle™ pediatric body array coil for Philips 3.0T MRI systems. Designed specifically for pediatric patients, the Snuggle coil has been optimized and validated for use with Philips 3.0T MRI systems, bringing enhanced comfort for children and efficient, high-quality i...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ABN Amro: Miss but strong capital, good set of results / Ahold Delhaize: Strong 4Q25 but no major surprise on FY26 adj. EPS guidance / Alfen: No recovery yet and another transitional year / BAM Group: Preview: 2026 outlook the key item / Econocom: Better REBITA, net debt, but EBIT below, much lower net profit, dividend halved, 2026-28 guidance postponed to “medium term” / Exor: Ferrari 4Q25 and 2026 guidance beat / Gecina: Results and guidance in line, DPS set to grow over 2026-30 / Heineken: No...

Oscar Rodriguez
  • Oscar Rodriguez

PHILIPS: RDOS. 4T’25 Y CAMBIO DE P.O. AL ALZA (ANÁLISIS BANCO SABADELL...

Rdos. 4T’25 vs 4T’24: Ventas: 5.097 M euros (+1,1% vs -0,9% BS(e) y -1,0% consenso); EBITA Aj.: 770 M euros (+13,4% vs +0,6% BS(e) y -1,0% consenso); BDI: 397 M euros (-333 M euros en 2024 vs 275 M euros BS(e) y 276 M euros consenso); Rdos. 2025 vs 2024: Ventas: 17.834 M euros (-1,0% vs -1,6% BS(e) y -1,6% consenso); EBITA Aj.: 2.195 M euros (+5,7% vs +1,5% BS(e) y +1,0% consenso); BDI: 897 M euros (-698 M euros en 2024 vs 775 M euros BS(e) y 776 M euros consenso).

ResearchPool Subscriptions

Get the most out of your insights

Get in touch